» Articles » PMID: 10961347

Differential Stimulation of Signaling Pathways Initiated by Edg-2 in Response to Lysophosphatidic Acid or Sphingosine-1-phosphate

Overview
Publisher Springer
Specialty Biology
Date 2000 Aug 29
PMID 10961347
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are produced during cell activation and have multiple effects on cells. A family of seven transmembrane-spanning domain G-protein-coupled receptors, named Edg, mediate these effects of LPA and S1P. In this study, transient overexpression of Edg-2 sensitized MG63 human osteosarcoma cells to both LPA- and S1P-mediated stimulation of fibronectin matrix deposition and actin stress fiber formation. Both lipids were active in the 1-20 nM concentration range on cells transfected with Edg-2 as compared to the 10-200 nM range on mock-transfected cells. The signaling pathway for matrix deposition by Edg-2-transfected cells was Rho dependent. Overexpression of Edg-2 also caused a tenfold decrease in the concentration of either LPA or S1P that activated MAPKinase (Erkl/2) in MG63 cells. LPA- or S1P-stimulated activation of Erkl/2 was Gi dependent. These results indicate that, in MG63 cells, Edg-2 mediates actin stress fiber formation, fibronectin matrix assembly, and MAPKinase activation in response to either LPA or S1P.

Citing Articles

LPA-induced suppression of periostin in human osteosarcoma cells is mediated by the LPA(1)/Egr-1 axis.

Windischhofer W, Huber E, Rossmann C, Semlitsch M, Kitz K, Rauh A Biochimie. 2012; 94(9):1997-2005.

PMID: 22659570 PMC: 3407874. DOI: 10.1016/j.biochi.2012.05.023.


Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms.

Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen A, Clezardin P Oncol Res. 2010; 18(4):173-84.

PMID: 20112503 PMC: 8485930. DOI: 10.3727/096504009790217399.


Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.

Boucharaba A, Serre C, Gres S, Saulnier-Blache J, Bordet J, Guglielmi J J Clin Invest. 2004; 114(12):1714-25.

PMID: 15599396 PMC: 535068. DOI: 10.1172/JCI22123.